A significant strategic transition is underway at Mainz-based biotechnology firm BioNTech. While news of the impending departure of its two founders has introduced an element of uncertainty, major market participants are sending a powerful counter-signal. Instead of withdrawing capital, prominent institutional investors are substantially increasing their stakes, placing a clear bet on the company’s next chapter of development.
A Strategic Shift from Vaccines to Oncology
The leadership transition coincides with a pivotal strategic refocus. The company is actively transforming from a pure-play COVID-19 vaccine manufacturer into a broadly diversified immunotherapy specialist. The core of this evolution is its oncology pipeline, which features promising candidates like Gotistobart, already in Phase III clinical trials. The long-term valuation of BioNTech is now fundamentally tied to the progress of this medical research, with the new management team tasked with proving its oncology candidates can hit critical milestones.
This research-intensive shift defines the financial outlook. Following fourth-quarter 2025 revenue of €907.4 million, management is targeting full-year 2026 revenues between €2.0 billion and €2.3 billion. After a prolonged period of pressure, the equity market is beginning to acknowledge this transformation. Having touched a 52-week low of €72.50 on March 10, the share price has rallied approximately 11% over the past seven days to trade at €80.70.
Should investors sell immediately? Or is it worth buying BioNTech?
Major Funds Amplify Their Positions
Recent portfolio adjustments reveal strong institutional conviction. Asset manager Dodge & Cox boosted its holding by a substantial 315.7%. In a significant move, pharmaceutical giant GSK established a new position in the Mainz company. This institutional interest is supported by positive analyst commentary. Deutsche Bank reiterated its Buy rating on Tuesday. In total, 13 analysts currently recommend purchasing the stock, reflected in a consensus average price target of $133.73.
The coming period will be decisive. The incoming leadership must demonstrate that the ambitious 2026 revenue targets are achievable and that progress in oncology can fundamentally justify the confidence being shown by these major investors.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from September 21 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 21.
BioNTech: Buy or sell? Read more here...
